- In April 2025, Teva Pharmaceuticals received FDA approval for its digital inhaler integrated with sensors and a mobile app to monitor asthma and COPD symptoms, enhancing real-time adherence tracking and management
- In April 2025, AstraZeneca, in collaboration with Honeywell, announced the development of next-generation inhalers using near-zero global warming potential (GWP) propellants, aiming to reduce the environmental impact of inhalers while maintaining effectiveness
- In February 2025, Propeller Health, a leading digital respiratory company, launched an AI-enhanced smart inhaler platform that uses predictive analytics to forecast asthma and COPD exacerbations, enabling patients and clinicians to intervene proactively and reduce hospitalizations
